Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma

Area of Science:

• Oncology
• Ophthalmology
• Molecular Biology

Background:

• Uveal melanoma (UM) is the most common primary ocular malignancy in adults.
• Metastasis, particularly to the liver, occurs in up to 50% of UM patients.
• The retinoblastoma (RB) pathway is frequently dysregulated in UM, making CDK4/6 inhibition a potential therapeutic strategy.

Purpose of the Study:

• To investigate the efficacy of a selective CDK4/6 inhibitor against metastatic UM.
• To explore the role of hepatocyte growth factor (HGF) in mediating resistance to CDK4/6 inhibition.
• To evaluate the combination of CDK4/6 inhibitors and cMET inhibitors for treating metastatic UM.

Main Methods:

• In vitro and in vivo studies using UM cell lines and xenograft models.
• Assessment of antiproliferative activity of a selective CDK4/6 inhibitor.
• Evaluation of combination therapy with cMET inhibitors in human-HGF knock-in mouse models.

Main Results:

• The CDK4/6 inhibitor demonstrated significant antiproliferative effects on UM cell lines.
• Hepatocyte growth factor (HGF) was found to reduce the efficacy of the CDK4/6 inhibitor.
• Combination therapy with cMET inhibitors enhanced growth suppression in metastatic UM models, especially in the presence of HGF.

Conclusions:

• CDK4/6 inhibition is a viable strategy for treating metastatic UM.
• HGF-mediated cMET signaling contributes to resistance against CDK4/6 inhibitors in UM.
• Combination therapy with cMET inhibitors offers a promising approach for overcoming resistance in metastatic UM, particularly in liver metastases.